|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1295642231 |
| 003 |
OCoLC |
| 005 |
20231120010631.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
220208s2022 mau o 000 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d YDX
|d OCLCO
|d OCLCF
|d NLW
|d N$T
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1294316705
|a 1294344013
|
| 020 |
|
|
|a 9780128244869
|q (electronic bk.)
|
| 020 |
|
|
|a 0128244860
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128244852
|
| 020 |
|
|
|z 0128244852
|
| 035 |
|
|
|a (OCoLC)1295642231
|z (OCoLC)1294316705
|z (OCoLC)1294344013
|
| 050 |
|
4 |
|a RC268.44.R37
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 245 |
0 |
0 |
|a RAS :
|b past, present, and future /
|c Edited by John P. O'Bryan, Gary A. Piazza.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource (1 volume)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in cancer research ;
|v volume 153
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a 1. A brief history of RAS and the RAS Initiative; Frank McCormick ; 2. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations; Rachel A. Burge and G. Aaron Hobbs ; 3. Drug targeting opportunities en route to Ras nanoclusters; Karolina Pavic, Rohan Chippalkatti, and Daniel Abankwa ; 4. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer; J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan-Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, and Channing J. Der ; 5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone; Alexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, and Gary A. Piazza ; 6. Targeting RAS oncogenesis with SOS1 inhibitors; Roman Christian Hillig and Benjamin Bader ; 7. Inhibition of SHP2 as an approach to block RAS-driven cancers; Yu-Ting Chou and Trever G. Bivona ; 8. Targeting the "undruggable#x94; RAS with biologics; Michael Whaby, Imran Khan, and John P. O'Bryan ; 9. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain; Jonathan M. DeLiberty, Ryan Robb, Claire E. Gates, and Kirsten L. Bryant ; 10. The RASopathies: Biology, genetics and therapeutic options; Jody Fromm Longo and Steven L. Carroll
|
| 650 |
|
0 |
|a Ras oncogenes.
|
| 650 |
|
2 |
|a Genes, ras
|0 (DNLM)D011905
|
| 650 |
|
6 |
|a Oncog�enes ras.
|0 (CaQQLa)201-0203645
|
| 650 |
|
7 |
|a Ras oncogenes
|2 fast
|0 (OCoLC)fst01090193
|
| 776 |
0 |
8 |
|i Print version:
|t RAS.
|d [Place of publication not identified] : ELSEVIER ACADEMIC PRESS, 2022
|z 0128244852
|w (OCoLC)1260665727
|
| 830 |
|
0 |
|a Advances in cancer research ;
|v v. 153.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/0065230X/153
|z Texto completo
|
